Takeda Pharmaceutical Company Limited (TAK)
The price, the headline numbers and the latest news, in one place.
Takeda Pharmaceutical Company Limited (TAK) Stock Price, Analysis & Data
| Bid | 18.41 |
| Market Cap | 58.7B |
| Revenue (ttm) | 4.62T |
| Net Income (ttm) | -163B |
| 0.10 | |
| -0.33 | |
| n/a | |
| 34.71 | |
| P/B (ttm) | 1.23 |
| P/S (ttm) | 0.01 |
| Earnings Date | Oct 29, 2026 |
| Ask | 18.42 |
| Volume | 589,546 |
| Avg. Volume (20D) | 3,230,785 |
| Open | 18.30 |
| Previous Close | 18.23 |
| Day's Range | 18.27 - 18.50 |
| 52-Week Range | 12.99 - 18.90 |
| Analyst | Strong<br>Buy |
| Price Target | 21.76 (18.39%) |
| Dividends | $0.62 (3.38%) |
| Ex-Dividend Date | Mar 31, 2026 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adyno...
Financial Performance
In 2026, Takeda Pharmaceutical Company's revenue was 4.51T, a decrease of -1.66% compared to the previous year's 4.58T. Earnings were -152.39B, a decrease of -241.2%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for TAK stock is "Strong Buy". The 12-month stock price forecast is 21.76, which is upside of 18.39% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $1.22T misses estimates by $0, with 10.23% YoY growth.
- EPS of 28.76 exceeds estimates by 10.14, with -55.06% YoY decline.
Analysts project revenue of ... Upgrade
